French innovation-focused mutual funds can make tax-efficient equity investments in ExonHit Therapeutics for renewable 3-year periods.
ExonHit Therapeutics has announced that it has obtained the Innovative Company accreditation from OSEO, the French state innovation agency. This means that French innovation-focused mutual funds can make tax-efficient equity investments in ExonHit Therapeutics for renewable 3-year periods.
“We are delighted to have received this OSEO accreditation, which emphasises our particularly innovative strategy in genomic profiling, which we apply both in therapeutics and in diagnostics,” said Loïc Maurel, President of ExonHit.
“We are continuing our investment and research efforts with a view to offering personalised medical solutions in Alzheimer’s disease and cancer.”
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
